Activity-based drug target discovery
Cancer and neurodegenerative diseases are known to develop and progress due to signalling abnormalities. We have developed cutting-edge proteomic analysis technologies to obtain 'real' signalling information from fresh frozen clinical samples.
Using these technologies, we have obtained proteome and phosphoproteome data and are investigating individual differences in signalling and how they are altered by treatment, with the aim of discovering new therapeutic targets and developing treatments.
Liquid biopsy diagnostics for precision medicine
We have developed large-scale sample processing technologies for biomarker discovery, primarily from extracellular vesicles in blood. Using these technologies, we have established methods to conduct large-scale biomarker candidate discovery and large-scale validation and applied them to various diseases.